anti-TGF-beta monoclonal antibody GC1008
(AN-tee ... BAY-tuh MAH-noh-KLOH-nul AN-tee-BAH-dee ...)
A substance being
studied in the treatment of breast cancer that has spread
to other parts of the body. It is also being studied in the
treatment of other cancers and conditions.
Anti-TGF-beta monoclonal antibody GC1008 binds to
a protein called transforming growth factor-beta
(TGF-beta), which is found on some cancer cells.
Anti-TGF-beta monoclonal antibody GC1008 may help
keep cancer cells from growing and prevent the growth of
new blood vessels that tumors need to grow. It is a type of
monoclonal antibody and a type of antiangiogenesis
agent. Also called fresolimumab and GC1008.